Benign prostatic hyperplasia (BPH) is condition that affects over 50% of men as they enter their fifth decade of life, often leading to lower urinary tract symptoms (LUTS). Primary treatment options include alpha blockers, 5-alpha reductase inhibitors, and phosphodiesterase-5 inhibitors. However, these medications can have some side effects, and there is a noticeable dearth of information addressing the long-term use of these medications. Thus, the exploration of all treatment modalities helps ensure patients receive personalized and effective care. Consequently, the primary objective of this review is to identify potential emerging medications for the treatment of BPH.
We conducted an extensive review of articles discussing pharmacotherapy for BPH spanning the last 15 years. Our information gathering process involved Scopus, PubMed-MEDLINE, Cochrane, Wiley Online Library Google Scholar, ClinicalTrials.gov, and the PharmaProjects database. This approach ensures that readers gain an in-depth knowledge of the existing therapeutic agents as well as promising avenues for managing BPH.
BPH treatment targets a patient's specific constellation of symptoms. Therefore, a broad knowledge base encompassing various treatment options is paramount in ensuring optimal treatment. Looking forward, the emphasis on personalization promises to reshape the landscape of BPH treatment and improve patient outcomes.
Expert opinion on emerging drugs. 2024 Jun 06 [Epub ahead of print]
Joshua Winograd, Nikit Venishetty, Alia Codelia-Anjum, Naeem Bhojani, Dean Elterman, Kevin C Zorn, Alexis Te, Bilal Chughtai
Department of Urology, Weill Cornell Medicine, New York, NY., Paul L. Foster School of Medicine, Texas Tech Health Sciences Center, El Paso, Texas., Division of Urology, University of Montreal, Montreal, QC., Division of Urology, University of Toronto, Toronto, ON.